Pilot Viability of 11C-MET-PET as a Post-surgery Baseline Scan in High-grade Gliomas
Pilot Feasibility of 11C-MET-PET as a Post-surgery Baseline Scan in the Follow-up of High-grade Gliomas for the Detection of Tumor Recurrence.
The tracer 11C-methionine (11 C-MET) is used as a specific cell proliferation tracer which shows metabolically active tumordeposities. A healthy brain barely takes up 11C-MET, causing the difference between the background and the tumor to be realively high. In addition, there is relatively little 11C-MET uptake in inflammatory processes. This makes 11C-MET a very suitable positron emission tomography (PET) tracer in order to differentiate between tumor progression and therapy changes. The latter is a major clinical problem for which further investigation is necessary.
In order to be able to make this differentiation, a direct post-operative baseline scan is required. With regard to the advanced MRI sequences, it is known that it is necessary to produce the post-operative baseline scan within 48 hours. After that timeframe, operation induced changes start to occur, such as granulation tissue. In that case the interpretation of the scan is no longer possible. Immediately postoperatively (<48 hours) 11C-MET has never been used before. Therefore, it is unknown whether 11C-MET provides a good baseline scan directly after surgery. This pilot will investigate the feasibility of this 11C-MET baseline scan and comparison the results with the advanced MRI sequences.
Studienübersicht
Status
Bedingungen
Detaillierte Beschreibung
Conventional MRI, advanced MRI and 11C-MET-PET will be conducted on the same day. The advanced MRI will consist of diffusion weighted imaging (DWI), perfusion imaging by contrast technique (DSC) and spectroscopy (MRS). The post-operative MRI and PET scan will be produced within 48 hours after surgery (with the aim that operative effects are not visible on the baseline scan). This corresponds to the current practice of conventional MRI follow-up at the end of the radiotherapy.
The comparison with the pre-operative scan is to assess the viability of the post-operative scan. It will assessed whether the preoperative tumor uptake will disappear in accordance to the resection, as shown by the advanced MRI sequences. In addition, it will be assessed whether there are no interfering postoperative effects. The 11C-MET-PET scans will be interpreted in comparison with the quantitative results obtained with advanced MRI sequences (perfusion / diffusion / oxygenation / spectroscopy). If an immediate postoperative 11C-MET-PET proves to be feasible, than this will provide a basis for further research. This future research consist out of the differentiation between tumor progression and therapy change, one of the most urgent clinical dilemmas in neuro-oncology.
Studientyp
Einschreibung (Voraussichtlich)
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Probenahmeverfahren
Studienpopulation
Patients with suspicion of newly diagnosed high-grade glioma eligible for standard therapy (surgical resection followed by chemoradiotherapy).
Patients with a second brain tumor, brain surgery earlier or prior radiotherapy to the brain are excluded. Patients with only a biopsy be excluded.
The group will consist of 10 patients. This number may be adjusted for patients who are found to have a different diagnosis after histological examination or fall out. For a pilot feasibility study our experience that a number of 10 patients is sufficient for PET examination.
Beschreibung
Inclusion Criteria:
- Patients with suspicion of newly diagnosed high-grade glioma who qualify for the standard treatment. Written informed consent
Exclusion Criteria:
- Patients with recurrent high-grade glioma or other brain tumor as a secondary diagnosis are excluded.
- In addition, all patients who have had previous brain surgery or radiotherapy to the brain are also excluded.
- Patients with only a biopsy will be excluded. Patients under the age of 18 years will not be included.
- General exclusion criteria for MRI are exclusion criteria for participation in this study. The general MRI exclusion criteria are: not MRI compatible ferromagnetic material, pregnancy (or presumption thereof) and claustrophobia.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
Kohorten und Interventionen
Gruppe / Kohorte |
|---|
|
High-grade Glioma Patients
Patients with suspicion of newly diagnosed high-grade glioma eligible for standard therapy (surgical resection followed by chemoradiotherapy). Patients with a second brain tumor, brain surgery earlier or prior radiotherapy to the brain are excluded. Patients with only a biopsy be excluded. The group will consist of 10 patients. This number may be adjusted for patients who are found to have a different diagnosis after histological examination or fall out. For a pilot feasibility study our experience that a number of 10 patients is sufficient for PET examination. |
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Visual comparison of pre- and post-surgery 11C-MET-PET
Zeitfenster: 1 week between pre- and post-surgery 11C-MET-PET
|
The 11C-MET-PET within 48 hours postoperatively will be assessed visually and quantitatively and compared with the preoperative 11C-MET-PET scan.
The 11C-MET-PET data will also be checked by comparison with the results of the advanced MRI sequences.
Specifically the comparison will include evaluation of surgical success (all former positive 11C-MET uptake removed) and evaluation of possible post-surgical effects on the second 11C-MET-PET.
|
1 week between pre- and post-surgery 11C-MET-PET
|
Mitarbeiter und Ermittler
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn
Primärer Abschluss (Voraussichtlich)
Studienabschluss (Voraussichtlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Schätzen)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Schätzen)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- NL50485.042.14
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Glioblastom
-
Milton S. Hershey Medical CenterRekrutierungGlioblastom | Glioblastoma multiforme | Glioblastoma multiforme, Erwachsener | Glioblastoma Multiforme des GehirnsVereinigte Staaten
-
Milton S. Hershey Medical CenterNational Cancer Institute (NCI)RekrutierungGlioblastom | Glioblastoma multiforme | Glioblastoma multiforme, Erwachsener | Glioblastoma Multiforme des GehirnsVereinigte Staaten
-
Jasper GerritsenMassachusetts General Hospital; Universitaire Ziekenhuizen KU Leuven; University... und andere MitarbeiterRekrutierungGlioblastom | Glioblastoma multiforme | Glioblastom, IDH-Wildtyp | Glioblastoma multiforme, Erwachsener | Glioblastoma Multiforme des GehirnsVereinigte Staaten, Belgien, Schweiz, Deutschland, Niederlande
-
University of UtahZurückgezogenGlioblastoma multiforme (GBM)Vereinigte Staaten
-
TVAX BiomedicalFDA Office of Orphan Products DevelopmentRekrutierungGlioblastoma Multiforme des GehirnsVereinigte Staaten
-
Shenzhen Geno-Immune Medical InstituteAnmeldung auf EinladungGlioblastoma multiforme | Glioblastoma Multiforme des GehirnsChina
-
University of Roma La SapienzaAbgeschlossenGlioblastoma Multiforme des Gehirns
-
Imperial College LondonRekrutierungGlioblastoma Multiforme des GehirnsVereinigtes Königreich
-
Clinique Neuro-OutaouaisAbgeschlossenGlioblastoma Multiforme des GehirnsKanada
-
University of Alabama at BirminghamNational Cancer Institute (NCI)Aktiv, nicht rekrutierendRezidivierendes Glioblastoma multiforme | Progressives Glioblastoma multiforme | Anaplastisches Astrozytom oder GliosarkomVereinigte Staaten